Ascendis Pharma A/S
TransCon PTH
hypoparathyroidism
Resolved
180days ago
Phase 2 readout · Jan 8, 2026
What's at stake
Phase 2 trial results for TransCon PTH in hypoparathyroidism are due Jan 8, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 15h ago
“Week 52 topline results from Phase 2 COACH Trial, which demonstrated improvements in annualized growth velocity across both TransCon CNP treatment-naïve and TransCon CNP-treated children that exceeded the 97th percentile of average stature ”